- Home
- ARL vs ELDN Comparison
ARL vs ELDN Comparison
Compare ARL & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- ELDN
- Stock Information
- Founded
- ARL 1999
- ELDN 2004
- Country
- ARL United States
- ELDN United States
- Employees
- ARL N/A
- ELDN N/A
- Industry
- ARL Building operators
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- ELDN Health Care
- Exchange
- ARL Nasdaq
- ELDN Nasdaq
- Market Cap
- ARL 251.2M
- ELDN 288.5M
- IPO Year
- ARL N/A
- ELDN N/A
- Fundamental
- Price
- ARL $13.91
- ELDN $4.29
- Analyst Decision
- ARL
- ELDN Strong Buy
- Analyst Count
- ARL 0
- ELDN 1
- Target Price
- ARL N/A
- ELDN $16.00
- AVG Volume (30 Days)
- ARL 4.3K
- ELDN 229.1K
- Earning Date
- ARL 03-21-2025
- ELDN 03-27-2025
- Dividend Yield
- ARL N/A
- ELDN N/A
- EPS Growth
- ARL N/A
- ELDN N/A
- EPS
- ARL N/A
- ELDN N/A
- Revenue
- ARL $51,029,000.00
- ELDN N/A
- Revenue This Year
- ARL N/A
- ELDN N/A
- Revenue Next Year
- ARL N/A
- ELDN N/A
- P/E Ratio
- ARL N/A
- ELDN N/A
- Revenue Growth
- ARL 0.87
- ELDN N/A
- 52 Week Low
- ARL $12.51
- ELDN $1.52
- 52 Week High
- ARL $22.77
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- ARL 47.20
- ELDN 44.28
- Support Level
- ARL $12.66
- ELDN $4.40
- Resistance Level
- ARL $13.40
- ELDN $4.65
- Average True Range (ATR)
- ARL 0.57
- ELDN 0.23
- MACD
- ARL -0.02
- ELDN -0.04
- Stochastic Oscillator
- ARL 58.06
- ELDN 8.16
About ARL American Realty Investors Inc.
American Realty Investors Inc is a real estate company. The company acquires, develops, and owns income-producing residential and commercial real estate properties. Its segment involves the Residential segment and the Commercial segment. The residential segment is engaged in the acquisition, development, ownership, and management of multifamily properties and the Commercial segment is engaged in the acquisition, ownership, and management of commercial real estate properties. Its holdings include apartments, office buildings, retail centers, and parcels of land.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.